9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
Published . Updated .
Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”
Source: BioPharma Dive
Acadia Healthcare (ACHC) since this story, compared with the market
Since the first closing price after “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe,” Acadia Healthcare (ACHC) is +8.55%. The S&P 500 fund (SPY) is -0.09% over the same days, a +8.64% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 23 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 6 days after publication, inside 30 days. The filing is listed beside the story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 12 days before publication, inside 30 days. The filing is listed beside the story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 51 days before publication, inside 60 days. The filing is listed beside the story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies mentioned with this story
- ACHC Acadia Healthcare
For “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
On 23 Sep 2026, “9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe” is the story that connects Acadia Healthcare (ACHC) to this story.
The link for Acadia Healthcare (ACHC) is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Acadia Healthcare (ACHC), and the dates in the story
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
How strong the case is around Acadia Healthcare (ACHC)
46 out of 100
“9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.